Serge Saxonov Sells 5,000 Shares of 10x Genomics (NASDAQ:TXG) Stock
by Scott Moore · The Cerbat Gem10x Genomics (NASDAQ:TXG – Get Free Report) CEO Serge Saxonov sold 5,000 shares of 10x Genomics stock in a transaction on Tuesday, April 14th. The stock was sold at an average price of $24.56, for a total transaction of $122,800.00. Following the sale, the chief executive officer owned 1,167,273 shares in the company, valued at $28,668,224.88. This represents a 0.43% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Serge Saxonov also recently made the following trade(s):
- On Tuesday, March 24th, Serge Saxonov sold 5,000 shares of 10x Genomics stock. The stock was sold at an average price of $19.52, for a total transaction of $97,600.00.
- On Monday, March 23rd, Serge Saxonov sold 10,000 shares of 10x Genomics stock. The stock was sold at an average price of $19.13, for a total transaction of $191,300.00.
- On Monday, February 23rd, Serge Saxonov sold 9,632 shares of 10x Genomics stock. The shares were sold at an average price of $18.58, for a total transaction of $178,962.56.
10x Genomics Stock Performance
NASDAQ TXG traded down $0.11 during trading on Thursday, reaching $25.24. The company’s stock had a trading volume of 1,798,590 shares, compared to its average volume of 2,560,033. The firm has a market cap of $3.22 billion, a price-to-earnings ratio of -72.11 and a beta of 2.17. 10x Genomics has a twelve month low of $7.25 and a twelve month high of $25.69. The business’s fifty day moving average price is $20.39 and its 200-day moving average price is $17.85.
10x Genomics (NASDAQ:TXG – Get Free Report) last posted its quarterly earnings data on Thursday, February 12th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.06. The company had revenue of $166.03 million for the quarter, compared to analyst estimates of $160.35 million. 10x Genomics had a negative net margin of 6.77% and a negative return on equity of 6.89%. 10x Genomics’s quarterly revenue was up .6% on a year-over-year basis. During the same period in the previous year, the business posted ($0.40) earnings per share. As a group, sell-side analysts forecast that 10x Genomics will post -1.43 EPS for the current fiscal year.
Analyst Ratings Changes
A number of research analysts have commented on TXG shares. Deutsche Bank Aktiengesellschaft set a $17.00 price objective on shares of 10x Genomics and gave the company a “hold” rating in a research note on Friday, February 13th. William Blair upgraded shares of 10x Genomics from a “market perform” rating to an “outperform” rating in a research note on Tuesday, March 31st. TD Cowen lifted their price objective on shares of 10x Genomics from $18.00 to $19.00 and gave the company a “hold” rating in a research note on Friday, February 13th. Leerink Partners lowered their target price on shares of 10x Genomics from $22.00 to $20.00 and set a “market perform” rating on the stock in a report on Tuesday, January 27th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 10x Genomics in a report on Friday, March 27th. Five investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, 10x Genomics presently has a consensus rating of “Hold” and a consensus target price of $19.46.
Read Our Latest Stock Report on 10x Genomics
Institutional Trading of 10x Genomics
A number of institutional investors have recently added to or reduced their stakes in the stock. Intech Investment Management LLC boosted its holdings in 10x Genomics by 1.4% during the fourth quarter. Intech Investment Management LLC now owns 40,047 shares of the company’s stock worth $653,000 after buying an additional 567 shares in the last quarter. Arizona State Retirement System boosted its holdings in 10x Genomics by 3.0% during the third quarter. Arizona State Retirement System now owns 29,586 shares of the company’s stock worth $346,000 after buying an additional 872 shares in the last quarter. Certuity LLC boosted its holdings in 10x Genomics by 4.7% during the fourth quarter. Certuity LLC now owns 20,204 shares of the company’s stock worth $330,000 after buying an additional 904 shares in the last quarter. Versant Capital Management Inc boosted its holdings in 10x Genomics by 3.3% during the third quarter. Versant Capital Management Inc now owns 29,364 shares of the company’s stock worth $343,000 after buying an additional 945 shares in the last quarter. Finally, True Wealth Design LLC boosted its holdings in 10x Genomics by 26.4% during the third quarter. True Wealth Design LLC now owns 4,534 shares of the company’s stock worth $53,000 after buying an additional 948 shares in the last quarter. Hedge funds and other institutional investors own 84.68% of the company’s stock.
About 10x Genomics
10x Genomics, Inc is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.
Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations.